1. Home
  2. EVC vs PRLD Comparison

EVC vs PRLD Comparison

Compare EVC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entravision Communications Corporation

EVC

Entravision Communications Corporation

HOLD

Current Price

$11.59

Market Cap

335.0M

Sector

Industrials

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$4.41

Market Cap

391.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVC
PRLD
Founded
1996
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
335.0M
391.1M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
EVC
PRLD
Price
$11.59
$4.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.67
AVG Volume (30 Days)
2.1M
560.9K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
5.35%
N/A
EPS Growth
47.59
23.21
EPS
0.13
N/A
Revenue
$536,034,000.00
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
$84.08
N/A
Revenue Growth
N/A
73.43
52 Week Low
$1.95
$0.75
52 Week High
$13.74
$5.69

Technical Indicators

Market Signals
Indicator
EVC
PRLD
Relative Strength Index (RSI) 55.82 47.21
Support Level $2.75 $3.92
Resistance Level $13.74 $4.69
Average True Range (ATR) 0.88 0.45
MACD -0.23 -0.04
Stochastic Oscillator 28.95 25.15

Price Performance

Historical Comparison
EVC
PRLD

About EVC Entravision Communications Corporation

Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: